European Association of Urology Guidelines on Renal Cell Carcinoma

The 2019 Update

Börje Ljungberg* (Corresponding Author), Laurance Albiges, Yasmin Abu-Ghanem, Karim Bensalah, Saeed Dabestani, Sergio Fernández Pello Montes, Rachel H. Giles, Fabian Hofmann, Milan Hora, Markus A. Kuczyk, Teele Kuusk, Thomas B. Lam, Lorenzo Marconi, Axel S. Merseburger, Thomas Powles, Michael Staehler, Rana Tahbaz, Alessandro Volpe, Axel Bex

*Corresponding author for this work

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

CONTEXT: The European Association of Urology Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC.

OBJECTIVE: To provide an updated RCC guideline based on standardised methodology including systematic reviews, which is robust, transparent, reproducible, and reliable.

EVIDENCE ACQUISITION: For the 2019 update, evidence synthesis was undertaken based on a comprehensive and structured literature assessment for new and relevant data. Where necessary, formal systematic reviews adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were undertaken. Relevant databases (Medline, Cochrane Libraries, trial registries, conference proceedings) were searched until June 2018, including randomised controlled trials (RCTs) and retrospective or controlled studies with a comparator arm, systematic reviews, and meta-analyses. Where relevant, risk of bias (RoB) assessment, and qualitative and quantitative syntheses of the evidence were performed. The remaining sections of the document were updated following a structured literature assessment. Clinical practice recommendations were developed and issued based on the modified GRADE framework.

EVIDENCE SYNTHESIS: All chapters of the RCC guidelines were updated based on a structured literature assessment, for prioritised topics based on the availability of robust data. For RCTs, RoB was low across studies. For most non-RCTs, clinical and methodological heterogeneity prevented pooling of data. The majority of included studies were retrospective with matched or unmatched cohorts, based on single- or multi-institutional data or national registries. The exception was for the treatment of metastatic RCC, for which there were several large RCTs, resulting in recommendations based on higher levels of evidence.

CONCLUSIONS: The 2019 RCC guidelines have been updated by the multidisciplinary panel using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2019.

PATIENT SUMMARY: The European Association of Urology Renal Cell Carcinoma Guideline Panel has thoroughly evaluated the available research data on kidney cancer to establish international standards for the care of kidney cancer patients.

Original languageEnglish
Pages (from-to)799-810
Number of pages12
JournalEuropean Urology
Volume75
Issue number5
Early online date23 Feb 2019
DOIs
Publication statusPublished - May 2019

Fingerprint

Renal Cell Carcinoma
Guidelines
Meta-Analysis
Randomized Controlled Trials
Kidney Neoplasms
Registries
Standard of Care
Libraries
Retrospective Studies
Databases
Research

Keywords

  • Diagnosis
  • European Association of Urology
  • Follow-up
  • Guidelines
  • Management
  • Medical
  • Renal cell cancer
  • Surgery
  • LYMPH-NODE DISSECTION
  • SYSTEMATIC REVIEWS
  • SURGICAL-MANAGEMENT
  • RADICAL NEPHRECTOMY
  • RANDOMIZED PHASE-3
  • ACTIVE SURVEILLANCE
  • PARTIAL NEPHRECTOMY
  • BOSNIAK CLASSIFICATION
  • OUTCOMES
  • KIDNEY CANCER

ASJC Scopus subject areas

  • Urology

Cite this

Ljungberg, B., Albiges, L., Abu-Ghanem, Y., Bensalah, K., Dabestani, S., Montes, S. F. P., ... Bex, A. (2019). European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. European Urology, 75(5), 799-810. https://doi.org/10.1016/j.eururo.2019.02.011

European Association of Urology Guidelines on Renal Cell Carcinoma : The 2019 Update. / Ljungberg, Börje (Corresponding Author); Albiges, Laurance; Abu-Ghanem, Yasmin; Bensalah, Karim; Dabestani, Saeed; Montes, Sergio Fernández Pello; Giles, Rachel H.; Hofmann, Fabian; Hora, Milan; Kuczyk, Markus A.; Kuusk, Teele; Lam, Thomas B.; Marconi, Lorenzo; Merseburger, Axel S.; Powles, Thomas; Staehler, Michael; Tahbaz, Rana; Volpe, Alessandro; Bex, Axel.

In: European Urology, Vol. 75, No. 5, 05.2019, p. 799-810.

Research output: Contribution to journalArticle

Ljungberg, B, Albiges, L, Abu-Ghanem, Y, Bensalah, K, Dabestani, S, Montes, SFP, Giles, RH, Hofmann, F, Hora, M, Kuczyk, MA, Kuusk, T, Lam, TB, Marconi, L, Merseburger, AS, Powles, T, Staehler, M, Tahbaz, R, Volpe, A & Bex, A 2019, 'European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update', European Urology, vol. 75, no. 5, pp. 799-810. https://doi.org/10.1016/j.eururo.2019.02.011
Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Montes SFP et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. European Urology. 2019 May;75(5):799-810. https://doi.org/10.1016/j.eururo.2019.02.011
Ljungberg, Börje ; Albiges, Laurance ; Abu-Ghanem, Yasmin ; Bensalah, Karim ; Dabestani, Saeed ; Montes, Sergio Fernández Pello ; Giles, Rachel H. ; Hofmann, Fabian ; Hora, Milan ; Kuczyk, Markus A. ; Kuusk, Teele ; Lam, Thomas B. ; Marconi, Lorenzo ; Merseburger, Axel S. ; Powles, Thomas ; Staehler, Michael ; Tahbaz, Rana ; Volpe, Alessandro ; Bex, Axel. / European Association of Urology Guidelines on Renal Cell Carcinoma : The 2019 Update. In: European Urology. 2019 ; Vol. 75, No. 5. pp. 799-810.
@article{dfb61158b3ba4f3094ed31575f462359,
title = "European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update",
abstract = "CONTEXT: The European Association of Urology Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC.OBJECTIVE: To provide an updated RCC guideline based on standardised methodology including systematic reviews, which is robust, transparent, reproducible, and reliable.EVIDENCE ACQUISITION: For the 2019 update, evidence synthesis was undertaken based on a comprehensive and structured literature assessment for new and relevant data. Where necessary, formal systematic reviews adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were undertaken. Relevant databases (Medline, Cochrane Libraries, trial registries, conference proceedings) were searched until June 2018, including randomised controlled trials (RCTs) and retrospective or controlled studies with a comparator arm, systematic reviews, and meta-analyses. Where relevant, risk of bias (RoB) assessment, and qualitative and quantitative syntheses of the evidence were performed. The remaining sections of the document were updated following a structured literature assessment. Clinical practice recommendations were developed and issued based on the modified GRADE framework.EVIDENCE SYNTHESIS: All chapters of the RCC guidelines were updated based on a structured literature assessment, for prioritised topics based on the availability of robust data. For RCTs, RoB was low across studies. For most non-RCTs, clinical and methodological heterogeneity prevented pooling of data. The majority of included studies were retrospective with matched or unmatched cohorts, based on single- or multi-institutional data or national registries. The exception was for the treatment of metastatic RCC, for which there were several large RCTs, resulting in recommendations based on higher levels of evidence.CONCLUSIONS: The 2019 RCC guidelines have been updated by the multidisciplinary panel using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2019.PATIENT SUMMARY: The European Association of Urology Renal Cell Carcinoma Guideline Panel has thoroughly evaluated the available research data on kidney cancer to establish international standards for the care of kidney cancer patients.",
keywords = "Diagnosis, European Association of Urology, Follow-up, Guidelines, Management, Medical, Renal cell cancer, Surgery, LYMPH-NODE DISSECTION, SYSTEMATIC REVIEWS, SURGICAL-MANAGEMENT, RADICAL NEPHRECTOMY, RANDOMIZED PHASE-3, ACTIVE SURVEILLANCE, PARTIAL NEPHRECTOMY, BOSNIAK CLASSIFICATION, OUTCOMES, KIDNEY CANCER",
author = "B{\"o}rje Ljungberg and Laurance Albiges and Yasmin Abu-Ghanem and Karim Bensalah and Saeed Dabestani and Montes, {Sergio Fern{\'a}ndez Pello} and Giles, {Rachel H.} and Fabian Hofmann and Milan Hora and Kuczyk, {Markus A.} and Teele Kuusk and Lam, {Thomas B.} and Lorenzo Marconi and Merseburger, {Axel S.} and Thomas Powles and Michael Staehler and Rana Tahbaz and Alessandro Volpe and Axel Bex",
note = "Copyright {\circledC} 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.",
year = "2019",
month = "5",
doi = "10.1016/j.eururo.2019.02.011",
language = "English",
volume = "75",
pages = "799--810",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - European Association of Urology Guidelines on Renal Cell Carcinoma

T2 - The 2019 Update

AU - Ljungberg, Börje

AU - Albiges, Laurance

AU - Abu-Ghanem, Yasmin

AU - Bensalah, Karim

AU - Dabestani, Saeed

AU - Montes, Sergio Fernández Pello

AU - Giles, Rachel H.

AU - Hofmann, Fabian

AU - Hora, Milan

AU - Kuczyk, Markus A.

AU - Kuusk, Teele

AU - Lam, Thomas B.

AU - Marconi, Lorenzo

AU - Merseburger, Axel S.

AU - Powles, Thomas

AU - Staehler, Michael

AU - Tahbaz, Rana

AU - Volpe, Alessandro

AU - Bex, Axel

N1 - Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

PY - 2019/5

Y1 - 2019/5

N2 - CONTEXT: The European Association of Urology Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC.OBJECTIVE: To provide an updated RCC guideline based on standardised methodology including systematic reviews, which is robust, transparent, reproducible, and reliable.EVIDENCE ACQUISITION: For the 2019 update, evidence synthesis was undertaken based on a comprehensive and structured literature assessment for new and relevant data. Where necessary, formal systematic reviews adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were undertaken. Relevant databases (Medline, Cochrane Libraries, trial registries, conference proceedings) were searched until June 2018, including randomised controlled trials (RCTs) and retrospective or controlled studies with a comparator arm, systematic reviews, and meta-analyses. Where relevant, risk of bias (RoB) assessment, and qualitative and quantitative syntheses of the evidence were performed. The remaining sections of the document were updated following a structured literature assessment. Clinical practice recommendations were developed and issued based on the modified GRADE framework.EVIDENCE SYNTHESIS: All chapters of the RCC guidelines were updated based on a structured literature assessment, for prioritised topics based on the availability of robust data. For RCTs, RoB was low across studies. For most non-RCTs, clinical and methodological heterogeneity prevented pooling of data. The majority of included studies were retrospective with matched or unmatched cohorts, based on single- or multi-institutional data or national registries. The exception was for the treatment of metastatic RCC, for which there were several large RCTs, resulting in recommendations based on higher levels of evidence.CONCLUSIONS: The 2019 RCC guidelines have been updated by the multidisciplinary panel using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2019.PATIENT SUMMARY: The European Association of Urology Renal Cell Carcinoma Guideline Panel has thoroughly evaluated the available research data on kidney cancer to establish international standards for the care of kidney cancer patients.

AB - CONTEXT: The European Association of Urology Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC.OBJECTIVE: To provide an updated RCC guideline based on standardised methodology including systematic reviews, which is robust, transparent, reproducible, and reliable.EVIDENCE ACQUISITION: For the 2019 update, evidence synthesis was undertaken based on a comprehensive and structured literature assessment for new and relevant data. Where necessary, formal systematic reviews adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were undertaken. Relevant databases (Medline, Cochrane Libraries, trial registries, conference proceedings) were searched until June 2018, including randomised controlled trials (RCTs) and retrospective or controlled studies with a comparator arm, systematic reviews, and meta-analyses. Where relevant, risk of bias (RoB) assessment, and qualitative and quantitative syntheses of the evidence were performed. The remaining sections of the document were updated following a structured literature assessment. Clinical practice recommendations were developed and issued based on the modified GRADE framework.EVIDENCE SYNTHESIS: All chapters of the RCC guidelines were updated based on a structured literature assessment, for prioritised topics based on the availability of robust data. For RCTs, RoB was low across studies. For most non-RCTs, clinical and methodological heterogeneity prevented pooling of data. The majority of included studies were retrospective with matched or unmatched cohorts, based on single- or multi-institutional data or national registries. The exception was for the treatment of metastatic RCC, for which there were several large RCTs, resulting in recommendations based on higher levels of evidence.CONCLUSIONS: The 2019 RCC guidelines have been updated by the multidisciplinary panel using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2019.PATIENT SUMMARY: The European Association of Urology Renal Cell Carcinoma Guideline Panel has thoroughly evaluated the available research data on kidney cancer to establish international standards for the care of kidney cancer patients.

KW - Diagnosis

KW - European Association of Urology

KW - Follow-up

KW - Guidelines

KW - Management

KW - Medical

KW - Renal cell cancer

KW - Surgery

KW - LYMPH-NODE DISSECTION

KW - SYSTEMATIC REVIEWS

KW - SURGICAL-MANAGEMENT

KW - RADICAL NEPHRECTOMY

KW - RANDOMIZED PHASE-3

KW - ACTIVE SURVEILLANCE

KW - PARTIAL NEPHRECTOMY

KW - BOSNIAK CLASSIFICATION

KW - OUTCOMES

KW - KIDNEY CANCER

UR - http://www.scopus.com/inward/record.url?scp=85061841950&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/european-association-urology-guidelines-renal-cell-carcinoma-2019-update

U2 - 10.1016/j.eururo.2019.02.011

DO - 10.1016/j.eururo.2019.02.011

M3 - Article

VL - 75

SP - 799

EP - 810

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 5

ER -